-
$ANVS closes its IPO of 2,300,000 shares of its common stock at $6.00 per share#AnnovisBio http://crweworld.com/symbol/ANVS -
Recent pharma happenings:
#AnnovisBio sells stock amid bull market, raises USD 12 Million;#Conatus Pharmaceuticals merges with Histogen, in an all-stock transaction;@Novartis gives up on making a#generic version of@GSK#Advair; https://delveinsight.com/blog/recent-pharma-happenings-for-annovis-gsk-histogen-conatus/ …#pharma#biotech#market -
Next we have is
#AnnovisBio CFO, Jeffrey McGroarty. Annovis Bio is in the mist of a phase II trial on ALZ and hoping to begin one for Parkinson’s in the near future.#IABCNLifeSciences20pic.twitter.com/iQ6HjUo9I1
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.